FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

스택 라이브러리

Recovery Sleep Stack

Recovery & Healingbeginner

80

상호작용

80
Share
펩타이드

2

일 평균 mcg

350

수준

beginner

추가됨

May 17, 2026

개요

The Recovery Sleep Stack pairs DSIP''s sleep-induction properties with BPC-157''s tissue repair, targeting the crucial intersection of sleep quality and physical recovery. This combination is used by athletes, post-surgical patients, and anyone whose recovery is limited by poor sleep quality. DSIP (Delta Sleep-Inducing Peptide) is a nonapeptide that increases slow-wave (delta) sleep — the stage during which human growth hormone is secreted and the majority of physical repair occurs. It also modulates cortisol and has demonstrated anxiolytic properties, helping the body transition into the parasympathetic state required for deep sleep. Unlike pharmaceutical sleep aids, DSIP does not cause next-day sedation or suppress REM sleep. The logic of pairing DSIP with BPC-157 is timing and amplification: DSIP increases the duration and depth of slow-wave sleep, which naturally elevates GH secretion and tissue repair signaling during the night. BPC-157 directly supports that same repair process by providing additional healing signals at the site of injury or stress. Together, they maximize what the body does during sleep anyway — repair and restore. This stack is administered in the evening, 30–60 minutes before sleep, allowing both peptides to act during the most anabolic phase of the 24-hour cycle. It is particularly effective during active injury recovery cycles and post-surgical rehabilitation, where optimizing sleep quality has the most direct impact on healing outcomes.

용량 프로토콜

DSIP

nightly· subcutaneous

DSIP에 대한 자세한 내용 →

100 mcg

1회 용량당

BPC-157

nightly· subcutaneous

BPC-157에 대한 자세한 내용 →

250 mcg

1회 용량당

목표 및 증거

Sleep qualityOvernight recoveryInjury healingCortisol reduction
증거 등급:동물 연구

Comments

Sign in to join the discussion

주의: 이 스택은 커뮤니티에서 제출된 것이며 연구용으로만 사용됩니다. Peptide Contacts는 제출된 스택의 안전성이나 효능을 검증하지 않습니다. 펩타이드 프로토콜을 사용하기 전에 항상 자격이 있는 의료 전문가와 상의하세요.